Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The REVIVE trial elucidates rusfertide’s capacity to maintain hematocrit levels below 45% during its 28-week study period, underscoring its potential as a transformative agent in the treatment of polycythemia vera. This efficacy, coupled with a favorable safety profile, marks a significant advancement in therapeutic options for this chronic condition.
Hematology March 4th 2024
Cleveland Clinic Journal of Medicine
For patients with cirrhosis facing venous thromboembolic events, the choice of anticoagulant—be it DOACs or LMWH—demands careful consideration of their unique hemostatic profile, emphasizing the need for personalized treatment strategies.
Gastroenterology February 22nd 2024
As healthcare moves forward, it’s crucial to balance quantitative data with the nuanced realities of patient experiences. This article explores the impact of the ‘quantitative fallacy’ on patient care and the importance of clinical judgment.
Hematology February 20th 2024
Hematology Advisor
In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.
Hematology February 12th 2024
Mayo Clinic
Understanding iron deficiency anemia’s impact on hemoglobin production and oxygen transport underscores the importance of addressing this common condition through diet, supplementation, and patient education.
Annals of Internal Medicine
The comparative modeling analysis of gene therapy for sickle cell disease underscores its potential cost-effectiveness and value in enhancing patient quality of life. With estimated ICERs significantly varying under different perspectives, the findings advocate for a nuanced approach to assessing novel therapies within the broader healthcare landscape.
Hematology February 7th 2024